Cibc World Markets Decreased Synchrony Finl (SYF) Stake by $806,284; Market Valuation Declined; Salem Investment Counselors Holding in Gilead Sciences (GILD) Trimmed as Stock Rose

May 23, 2018 - By David King

Synchrony Financial (NYSE:SYF) Logo

Salem Investment Counselors Inc decreased its stake in Gilead Sciences Inc (GILD) by 22.85% based on its latest 2017Q4 regulatory filing with the SEC. Salem Investment Counselors Inc sold 21,230 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 71,667 shares of the health care company at the end of 2017Q4, valued at $5.13 million, down from 92,897 at the end of the previous reported quarter. Salem Investment Counselors Inc who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $88.46B market cap company. The stock increased 0.29% or $0.2 during the last trading session, reaching $68.03. About 799,932 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 23, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Cibc World Markets Inc decreased its stake in Synchrony Finl (SYF) by 32.22% based on its latest 2017Q4 regulatory filing with the SEC. Cibc World Markets Inc sold 21,218 shares as the company’s stock declined 15.73% with the market. The institutional investor held 44,631 shares of the consumer services company at the end of 2017Q4, valued at $1.72 million, down from 65,849 at the end of the previous reported quarter. Cibc World Markets Inc who had been investing in Synchrony Finl for a number of months, seems to be less bullish one the $27.07 billion market cap company. The stock decreased 0.67% or $0.241 during the last trading session, reaching $35.869. About 792,471 shares traded. Synchrony Financial (NYSE:SYF) has declined 0.21% since May 23, 2017 and is downtrending. It has underperformed by 11.76% the S&P500.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It worsened, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Woodley Farra Manion Portfolio Management Incorporated owns 201,558 shares or 1.59% of their US portfolio. B And T Capital Dba Alpha Capital accumulated 1.12% or 33,038 shares. Proshare Advsrs Limited Liability Corporation invested 0.61% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Clark Estates Inc Ny holds 0.57% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 48,050 shares. Magnetar Lc reported 0.05% in Gilead Sciences, Inc. (NASDAQ:GILD). 14,383 were accumulated by Exane Derivatives. Alpha Windward Limited Liability Corporation stated it has 2,805 shares or 0.12% of all its holdings. 25,980 were reported by Hallmark Management. New York-based Quinn Opportunity Ptnrs Ltd Liability Corporation has invested 0.74% in Gilead Sciences, Inc. (NASDAQ:GILD). Bbva Compass Retail Bank Incorporated accumulated 0.05% or 11,793 shares. Holowesko Ptnrs reported 1.22M shares. Smithfield Tru Communication accumulated 4,872 shares or 0.04% of the stock. Symphony Asset Management Ltd Liability reported 21,097 shares or 0.15% of all its holdings. Sol Cap reported 0.21% stake. The New York-based Guardian Life Of America has invested 0.07% in Gilead Sciences, Inc. (NASDAQ:GILD).

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Bizjournals.com which released: “He helped Gilead score billions from HIV, hepatitis C drugs — now he’s building a cancer fighter” on May 23, 2018, also Seekingalpha.com with their article: “Gilead: Where’s The Next Catalyst?” published on May 18, 2018, Seekingalpha.com published: “Gilead: What A Disaster” on May 08, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)” published on May 16, 2018 as well as Nasdaq.com‘s news article titled: “3 Biotechs on the FDA’s Naughty List That Should Be on Investors’ Buy Lists” with publication date: May 22, 2018.

Salem Investment Counselors Inc, which manages about $1.19B and $922.89 million US Long portfolio, upped its stake in Intel Corp (NASDAQ:INTC) by 10,765 shares to 346,866 shares, valued at $16.01M in 2017Q4, according to the filing. It also increased its holding in Merck & Co Inc (NYSE:MRK) by 60,334 shares in the quarter, for a total of 224,432 shares, and has risen its stake in Netflix Inc (NASDAQ:NFLX).

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.43 earnings per share, down 43.03% or $1.08 from last year’s $2.51 per share. GILD’s profit will be $1.86 billion for 11.89 P/E if the $1.43 EPS becomes a reality. After $1.37 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 4.38% EPS growth.

Since January 2, 2018, it had 0 insider purchases, and 22 selling transactions for $44.80 million activity. On Friday, April 27 the insider Cogan John Francis sold $431,117. Alton Gregg H sold $2.37M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, January 11. On Tuesday, January 16 Meyers James R sold $8.02M worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 100,000 shares. Washington Robin L also sold $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, February 21. WILSON GAYLE E had sold 60,000 shares worth $4.68 million.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 130 analyst reports since July 29, 2015 according to SRatingsIntel. Leerink Swann maintained the shares of GILD in report on Thursday, October 5 with “Market Perform” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Monday, November 13 by Argus Research. As per Wednesday, October 4, the company rating was initiated by Oppenheimer. On Friday, October 27 the stock rating was maintained by BMO Capital Markets with “Outperform”. Needham downgraded the stock to “Hold” rating in Tuesday, July 26 report. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Equal-Weight” rating by Morgan Stanley on Wednesday, May 2. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Outperform” rating given on Wednesday, January 20 by Credit Suisse. The stock has “Buy” rating by Mizuho on Sunday, October 29. As per Thursday, February 22, the company rating was maintained by Leerink Swann. BMO Capital Markets maintained the shares of GILD in report on Tuesday, January 2 with “Hold” rating.

Cibc World Markets Inc, which manages about $22.10 billion US Long portfolio, upped its stake in Pembina Pipeline Corp (NYSE:PBA) by 6.78 million shares to 7.28 million shares, valued at $263.56M in 2017Q4, according to the filing. It also increased its holding in Ubs Group Ag (NYSE:UBS) by 83,458 shares in the quarter, for a total of 162,044 shares, and has risen its stake in Proshares Tr (NOBL).

Among 30 analysts covering Synchrony Financial (NYSE:SYF), 22 have Buy rating, 1 Sell and 7 Hold. Therefore 73% are positive. Synchrony Financial had 77 analyst reports since July 20, 2015 according to SRatingsIntel. Stephens maintained it with “Hold” rating and $42.0 target in Wednesday, January 3 report. As per Wednesday, April 12, the company rating was maintained by Wood. The stock has “Buy” rating by BMO Capital Markets on Friday, July 21. The firm has “Buy” rating given on Wednesday, May 31 by BMO Capital Markets. DA Davidson initiated it with “Buy” rating and $37.0 target in Wednesday, January 13 report. RBC Capital Markets maintained the shares of SYF in report on Tuesday, April 17 with “Buy” rating. On Wednesday, June 7 the stock rating was maintained by Jefferies with “Buy”. Deutsche Bank maintained the stock with “Buy” rating in Wednesday, May 4 report. The firm has “Buy” rating given on Monday, November 23 by Sterne Agee CRT. Barclays Capital maintained the stock with “Overweight” rating in Monday, October 23 report.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: